Trinity Biotech plc
NASDAQ:TRIBMedical - Diagnostics & Research
-$0.51 today
- Market cap
- $117.96M
- Beta
- 1.00
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$60.27
Volume 0.00M
Average 1.34M
Income Statement
Follow revenue through to earnings.
Revenue
$43.78M
FY 2025 · Annual
-28.9% YoYOperating Income
-$11.42M
FY 2025 · Annual
Net Income
-$37.38M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 81.15M | 62.52M | 56.83M | 61.56M | 43.79M |
| Cost of Revenue | 54.89M | 52.73M | 37.38M | 40.11M | 26.9M |
| Gross Profit | 33.45M | 22.05M | 19.45M | 21.44M | 16.89M |
| Gross Margin | 41.2% | 35.3% | 34.2% | 34.8% | 38.6% |
| Research & Development | 4.5M | 4.14M | 4.38M | 4.54M | 3.63M |
| Selling, General & Admin | 24.68M | 29.17M | 31.15M | 28.82M | 24.67M |
| Operating Expenses | 29.52M | 32.96M | 46.5M | 42.61M | 28.3M |
| Depreciation & Amortization | 2.74M | 2.33M | 1.78M | 1.87M | 2.68M |
| EBITDA | 10.59M | (16.71M) | (24.1M) | (16.91M) | (21.38M) |
| EBITDA Margin | 13.1% | -26.7% | -42.4% | -27.5% | -48.8% |
| Operating Income | 3.94M | (15.27M) | (27.05M) | (21.17M) | (11.42M) |
| Operating Margin | 4.9% | -24.4% | -47.6% | -34.4% | -26.1% |
| Interest Income | 1.22M | 303K | 1.17M | 0 | 221K |
| Interest Expense | 7.1M | 24.73M | 10.15M | 9.57M | 13.11M |
| Other Income / Expenses | (5.86M) | (24.43M) | (9.88M) | (9.57M) | (25.76M) |
| Income Before Tax | (1.92M) | (43.78M) | (36.93M) | (30.73M) | (37.18M) |
| Pre-Tax Margin | -2.4% | -70.0% | -65.0% | -49.9% | -84.9% |
| Income Tax Expense | (74K) | (194K) | (59K) | 486K | 199K |
| Net Income | 875K | (41M) | (24.02M) | (31.79M) | (37.38M) |
| Net Margin | 1.1% | -65.6% | -42.3% | -51.6% | -85.4% |
| EPS (Basic) | 6.30 | (180.00) | (96.00) | (52.98) | (60.00) |
| EPS (Diluted) | 4.92 | (156.00) | (96.00) | (52.98) | (60.00) |
| 139.34K | 224.9K | 255.17K | 598.65K | 619.19K | |
| 177.53K | 259.16K | 255.17K | 598.65K | 619.19K |
TRIB Earnings Waterfall · TTM
NASDAQ:TRIB · Revenue to Net Income
Key Ratios
Analysis
$43.9M of revenue converted into -$37.4M of net income for the selected period. Gross margin is 33.7% and net margin is -91.3%, showing how much revenue survives after costs and taxes. EPS is $-60.60, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
No competitor data available.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 12, 2026 | |
| SC 13D/A | SC 13D/A filing | Nov 10, 2026 | |
| 6-K | 6-K filing | Oct 5, 2026 | |
| 6-K | 6-K filing | Sep 9, 2026 | |
| 6-K | 6-K filing | Sep 8, 2026 |
How much revenue does TRIB generate?
Trinity Biotech plc (TRIB) reported $43.78M of revenue in fiscal 2025.
Is TRIB profitable?
Trinity Biotech plc (TRIB) reported -$37.38M of net income, with a net margin of -85.4%.
Continue the stock analysis
Jump to another research area for this company.